• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

终末期肾病腹膜透析患者使用L-肉碱的当前观点

Current Opinion on Usage of L-Carnitine in End-Stage Renal Disease Patients on Peritoneal Dialysis.

作者信息

Bonomini Mario, Di Liberato Lorenzo, Zammit Victor, Arduini Arduino

机构信息

Department of Medicine, Section of Nephrology and Dialysis, G. d'Annunzio University, SS. Annunziata Hospital, 66100 Chieti, Italy.

Clinical Sciences Research Institute, Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK.

出版信息

Molecules. 2019 Sep 23;24(19):3449. doi: 10.3390/molecules24193449.

DOI:10.3390/molecules24193449
PMID:31547545
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6803867/
Abstract

The advantages of peritoneal dialysis (PD) over hemodialysis (HD) are well-documented. Notwithstanding, only a small proportion of patients with end-stage renal disease (ESRD) are managed with PD. This may be related to the high glucose load that PD solutions in current use have on the patient. The effects of such excess glucose include the relatively early limitation of the ultrafiltration capacity of the peritoneal membrane, and the metabolic effects associated with hyperglycemia, e.g., decreased insulin sensitivity. This article describes the advantages that may be realized by the glucose-sparing effects of substituting part of the glucose load with other osmotically active metabolites, particularly L-carnitine. The latter is anticipated to have metabolic advantages of its own, especially as in PD patients, high plasma concentrations can be achieved in the absence of renal clearance. Besides its better biocompatibility, L-carnitine demonstrates anti-anemia action due to its effects on erythropoiesis, and positive effects on the longevity and deformability of erythrocytes. Observations from our trials on the use of carnitine-enriched PD solutions have demonstrated the effectiveness of L-carnitine as an efficient osmolyte in PD, and its favorable effect on the insulin sensitivity of the patients. The significance of these findings for future developments in the use of PD in the management of patients with ESRD is discussed.

摘要

腹膜透析(PD)相对于血液透析(HD)的优势已有充分记录。尽管如此,终末期肾病(ESRD)患者中只有一小部分接受腹膜透析治疗。这可能与目前使用的腹膜透析液对患者的高葡萄糖负荷有关。这种过量葡萄糖的影响包括腹膜超滤能力相对较早受限,以及与高血糖相关的代谢影响,例如胰岛素敏感性降低。本文描述了用其他具有渗透活性的代谢物(特别是L-肉碱)替代部分葡萄糖负荷所带来的节省葡萄糖效应可能实现的优势。预计L-肉碱自身具有代谢优势,尤其是在腹膜透析患者中,在没有肾脏清除功能的情况下也能达到较高的血浆浓度。除了具有更好的生物相容性外,L-肉碱因其对红细胞生成的影响而具有抗贫血作用,并且对红细胞的寿命和可变形性有积极影响。我们关于使用富含肉碱的腹膜透析液的试验观察结果表明,L-肉碱作为腹膜透析中一种有效的渗透剂是有效的,并且对患者的胰岛素敏感性有有利影响。本文讨论了这些发现对未来在终末期肾病患者管理中使用腹膜透析的发展的意义。

相似文献

1
Current Opinion on Usage of L-Carnitine in End-Stage Renal Disease Patients on Peritoneal Dialysis.终末期肾病腹膜透析患者使用L-肉碱的当前观点
Molecules. 2019 Sep 23;24(19):3449. doi: 10.3390/molecules24193449.
2
A New Peritoneal Dialysis Solution Containing L-Carnitine and Xylitol for Patients on Continuous Ambulatory Peritoneal Dialysis: First Clinical Experience.一种含左旋肉碱和木糖醇的新型腹膜透析液用于持续性非卧床腹膜透析患者:首次临床经验
Toxins (Basel). 2021 Feb 24;13(3):174. doi: 10.3390/toxins13030174.
3
A Novel Formulation of Glucose-Sparing Peritoneal Dialysis Solutions with l-Carnitine Improves Biocompatibility on Human Mesothelial Cells.新型含左旋肉碱葡萄糖节约型腹膜透析液改善对人腹膜间皮细胞的生物相容性。
Int J Mol Sci. 2020 Dec 24;22(1):123. doi: 10.3390/ijms22010123.
4
L-carnitine is an osmotic agent suitable for peritoneal dialysis.左旋肉碱是一种适合腹膜透析的渗透剂。
Kidney Int. 2011 Sep;80(6):645-54. doi: 10.1038/ki.2011.117. Epub 2011 Apr 27.
5
Effect of an L-carnitine-containing peritoneal dialysate on insulin sensitivity in patients treated with CAPD: a 4-month, prospective, multicenter randomized trial.含左旋肉碱腹膜透析液对 CAPD 患者胰岛素敏感性的影响:一项为期 4 个月的前瞻性、多中心、随机试验。
Am J Kidney Dis. 2013 Nov;62(5):929-38. doi: 10.1053/j.ajkd.2013.04.007. Epub 2013 May 29.
6
How to Improve the Biocompatibility of Peritoneal Dialysis Solutions (without Jeopardizing the Patient's Health).如何提高腹膜透析液的生物相容性(同时不损害患者健康)。
Int J Mol Sci. 2021 Jul 26;22(15):7955. doi: 10.3390/ijms22157955.
7
[L-carnitine in peritoneal dialysis].[腹膜透析中的左旋肉碱]
G Ital Nefrol. 2011 Jul-Aug;28(4):393-400.
8
A New Method to Increase Ultrafiltration in Peritoneal Dialysis: Steady Concentration Peritoneal Dialysis.一种增加腹膜透析超滤的新方法:稳定浓度腹膜透析。
Perit Dial Int. 2016;36(5):555-61. doi: 10.3747/pdi.2016.00007. Epub 2016 Jun 9.
9
Peritoneal dialysis: a primary care perspective.腹膜透析:初级保健视角
J Am Board Fam Med. 2006 Jul-Aug;19(4):380-9. doi: 10.3122/jabfm.19.4.380.
10
Bimodal dialysis: an integrated approach to renal replacement therapy.双峰透析:一种肾脏替代治疗的综合方法。
Perit Dial Int. 2004 Nov-Dec;24(6):547-53.

引用本文的文献

1
Glycemic Control in Patients with Diabetes on Peritoneal Dialysis: From Glucose Sparing Approach to Glucose Monitoring.腹膜透析糖尿病患者的血糖控制:从节约葡萄糖方法到血糖监测
Life (Basel). 2025 May 17;15(5):798. doi: 10.3390/life15050798.
2
Coupling Osmotic Efficacy with Biocompatibility in Peritoneal Dialysis: A Stiff Challenge.在腹膜透析中实现渗透效能与生物相容性的偶联:一项艰巨的挑战。
Int J Mol Sci. 2024 Mar 20;25(6):3532. doi: 10.3390/ijms25063532.
3
l-carnitine: Nutrition, pathology, and health benefits.左旋肉碱:营养、病理学及健康益处。
Saudi J Biol Sci. 2023 Feb;30(2):103555. doi: 10.1016/j.sjbs.2022.103555. Epub 2022 Dec 30.
4
Fibrosis of Peritoneal Membrane as Target of New Therapies in Peritoneal Dialysis.腹膜纤维化:腹膜透析治疗新靶点。
Int J Mol Sci. 2022 Apr 27;23(9):4831. doi: 10.3390/ijms23094831.
5
How to Improve the Biocompatibility of Peritoneal Dialysis Solutions (without Jeopardizing the Patient's Health).如何提高腹膜透析液的生物相容性(同时不损害患者健康)。
Int J Mol Sci. 2021 Jul 26;22(15):7955. doi: 10.3390/ijms22157955.
6
Biological Effects of XyloCore, a Glucose Sparing PD Solution, on Mesothelial Cells: Focus on Mesothelial-Mesenchymal Transition, Inflammation and Angiogenesis.木芯糖聚电解质(XyloCore),一种节约葡萄糖的 PD 溶液,对间皮细胞的生物学效应:关注间皮-间质转化、炎症和血管生成。
Nutrients. 2021 Jun 30;13(7):2282. doi: 10.3390/nu13072282.
7
A New Peritoneal Dialysis Solution Containing L-Carnitine and Xylitol for Patients on Continuous Ambulatory Peritoneal Dialysis: First Clinical Experience.一种含左旋肉碱和木糖醇的新型腹膜透析液用于持续性非卧床腹膜透析患者:首次临床经验
Toxins (Basel). 2021 Feb 24;13(3):174. doi: 10.3390/toxins13030174.
8
A Novel Formulation of Glucose-Sparing Peritoneal Dialysis Solutions with l-Carnitine Improves Biocompatibility on Human Mesothelial Cells.新型含左旋肉碱葡萄糖节约型腹膜透析液改善对人腹膜间皮细胞的生物相容性。
Int J Mol Sci. 2020 Dec 24;22(1):123. doi: 10.3390/ijms22010123.
9
Proteomic Research in Peritoneal Dialysis.腹膜透析中的蛋白质组学研究。
Int J Mol Sci. 2020 Jul 31;21(15):5489. doi: 10.3390/ijms21155489.
10
Association between carnitine deficiency and the erythropoietin resistance index in patients undergoing peritoneal dialysis: a cross-sectional observational study.肉碱缺乏与腹膜透析患者红细胞生成素抵抗指数的关系:一项横断面观察性研究。
Ren Fail. 2020 Nov;42(1):146-153. doi: 10.1080/0886022X.2020.1719847.

本文引用的文献

1
Cost Effectiveness of Dialysis Modalities: A Systematic Review of Economic Evaluations.透析模式的成本效益:经济评估的系统综述。
Appl Health Econ Health Policy. 2019 Jun;17(3):315-330. doi: 10.1007/s40258-018-00455-2.
2
Biocompatible Peritoneal Dialysis: The Target Is Still Way Off.生物相容性腹膜透析:目标仍遥不可及。
Front Physiol. 2019 Jan 7;9:1853. doi: 10.3389/fphys.2018.01853. eCollection 2018.
3
Role of carnitine and its derivatives in the development and management of type 2 diabetes.肉碱及其衍生物在 2 型糖尿病的发生发展和治疗中的作用。
Nutr Diabetes. 2018 Mar 7;8(1):8. doi: 10.1038/s41387-018-0017-1.
4
Effect of Flavin-Containing Monooxygenase Genotype, Mouse Strain, and Gender on Trimethylamine -oxide Production, Plasma Cholesterol Concentration, and an Index of Atherosclerosis.黄素单加氧酶基因型、小鼠品系和性别对氧化三甲胺产生、血浆胆固醇浓度和动脉粥样硬化指数的影响。
Drug Metab Dispos. 2018 Jan;46(1):20-25. doi: 10.1124/dmd.117.077636. Epub 2017 Oct 25.
5
Risk of new-onset diabetes in end-stage renal disease patients undergoing dialysis: analysis from registry data of Taiwan.台湾透析终末期肾病患者新发糖尿病的风险:来自登记数据的分析。
Nephrol Dial Transplant. 2018 Apr 1;33(4):670-675. doi: 10.1093/ndt/gfx250.
6
Icodextrin and peritoneal dialysis: advantages and new applications.艾考糊精与腹膜透析:优势及新应用
Int Urol Nephrol. 2018 Mar;50(3):495-500. doi: 10.1007/s11255-017-1647-2. Epub 2017 Jul 3.
7
Low GDP Solution and Glucose-Sparing Strategies for Peritoneal Dialysis.腹膜透析的低GDP解决方案与葡萄糖节约策略
Semin Nephrol. 2017 Jan;37(1):30-42. doi: 10.1016/j.semnephrol.2016.10.005.
8
Effect of peritoneal dialysis fluid containing osmo-metabolic agents on human endothelial cells.含渗透代谢剂的腹膜透析液对人内皮细胞的影响。
Drug Des Devel Ther. 2016 Nov 28;10:3925-3932. doi: 10.2147/DDDT.S117078. eCollection 2016.
9
The Current State of Peritoneal Dialysis.腹膜透析的现状
J Am Soc Nephrol. 2016 Nov;27(11):3238-3252. doi: 10.1681/ASN.2016010112. Epub 2016 Jun 23.
10
Gut hormone secretion, gastric emptying, and glycemic responses to erythritol and xylitol in lean and obese subjects.瘦人和肥胖者对赤藓糖醇和木糖醇的肠道激素分泌、胃排空及血糖反应
Am J Physiol Endocrinol Metab. 2016 Jun 1;310(11):E1053-61. doi: 10.1152/ajpendo.00037.2016. Epub 2016 Apr 26.